[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649591":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":41,"centralContacts":42,"locations":41,"responsibleParty":48,"collaborators":41,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":41,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":41,"enrollmentInfo":59,"targetDuration":41,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":73,"whyStopped":41,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":41},{"fullName":5,"class":6},"University of Maryland, Baltimore","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"OLP-EXP","EXPERIMENTAL","Expectation optimization addressing benefit, personal-control, and coping expectations, plus transparent daily OLP pills for 6 weeks and weekly boosters.",[13],"Other: OLP-EXP",{"label":15,"type":10,"description":16,"interventionNames":17},"EXP","Expectation optimization addressing personal-control and coping expectations associated with chronic pain in general, plus weekly boosters.",[18],"Behavioral: EXP",{"label":20,"type":21,"description":22,"interventionNames":23},"OLP","ACTIVE_COMPARATOR","Standard transparent OLP rationale and daily OLP pills for 6 weeks, with neutral matched study contacts that do not deliver expectation-optimization content.",[24],"Dietary Supplement: OLP",[26,32,37],{"type":6,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"Expectation optimization addressing benefit, personal control, and coping expectations, plus transparent daily OLP pills for 6 weeks and weekly boosters.",[9],[30,31],"Zeebo pills","Expectations optimization intervention",{"type":33,"name":20,"description":34,"armGroupLabels":35,"otherNames":36},"DIETARY_SUPPLEMENT","Open-label placebo pills. The placebo pills in this study are empty capsules without any ingredients inside. The capsules are made of microcrystalline cellulose.",[20],[30],{"type":38,"name":15,"description":16,"armGroupLabels":39,"otherNames":40},"BEHAVIORAL",[15],[31],null,[43],{"name":44,"role":45,"phone":46,"phoneExt":41,"email":47},"Yang Wang, PhD","CONTACT","410-706-7824","yang.wang@umaryland.edu",{"type":49,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100649591","feasibility-and-acceptability-of-olp-exp-in-chronic-pain-100649591",false,"NCT07735520","Feasibility and Acceptability of OLP-EXP in Chronic Pain","Evaluating the Feasibility and Acceptability of Expectation-optimized Open-label Placebo as an Adjuvant Treatment for Chronic Pain","Inclusion Criteria:\n\n* English speaking (written and spoken)\n* Age between 18 and 65 years\n* Confirmed TMD for more than 3 months\n* Grade II or above on the Graded Chronic Pain Scale\n\nExclusion Criteria:\n\n* Personal (or family first degree) history of mania, schizophrenia, or other psychoses\n* Severe psychiatric conditions require medication (e.g. schizophrenia, bipolar disorders, autism) or hospitalization within the last 3 years.\n* Lifetime alcohol\u002Fdrug dependence and alcohol\u002Fdrug abuse in past one year\n* Pregnancy\u002FBreastfeeding\n* Currently participating in another clinical trial","ALL","18 Years",{"count":60,"type":61},57,"ESTIMATED","INTERVENTIONAL",[64],"NA","The primary objective is to determine the feasibility of delivering OLP-EXP, EXP only, and OLP only over 6 weeks to adults with chronic TMD. The trial will be considered feasible for progression planning when the 6-week retention rate is at least 80% in each arm and average OLP pill adherence is at least 80% of prescribed days in each OLP arm.\n\nPrimary hypothesis: Each intervention arm will meet the prespecified 6-week retention benchmark, and each OLP arm will meet the prespecified pill-adherence benchmark.\n\nThe secondary objectives are:\n\n1. To evaluate acceptability of each intervention using the TFA measurement and semi-structured interviews.\n2. To assess the feasibility of collecting daily EMA, continuous actigraphy, weekly questionnaires, and 3-, 6-, and 12-month follow-up assessments.\n3. To identify intervention barriers, facilitators, perceived benefits, burden, ethical concerns, and recommendations for a future fully powered efficacy trial.\n4. To estimate variability, missingness, and measure reliability needed to select outcomes and design a future trial.",[67],"Temporomandibular Disorders (TMD)",[69,70,71,72],"expectations","chronic pain management","open-label placebo","psychological interventions","NOT_YET_RECRUITING","2026-07-24",{"date":76,"type":77},"2026-07-30","ACTUAL",{"date":79,"type":61},"2027-07-01",{"date":81,"type":61},"2029-12-31",{"name":5,"class":6}]